Adverum Biotechnologies, Inc. (ADVM)

NASDAQ: ADVM · IEX Real-Time Price · USD

11.34

+0.19 (1.70%)

At close: Apr 19, 2024, 4:00 PM

11.70

+0.36 (3.17%)

After-hours: Apr 19, 2024, 7:34 PM EDT

Adverum Biotechnologies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Net Income	-117.17	-154.54	-145.54	-117.51	-64.49	-72.63	-56.15	-113.75	-47.45	-28.63	Upgrade
Depreciation & Amortization	18.67	10.57	4.65	4.16	1.57	1.75	2.1	1.6	0.81	0.16	Upgrade
Share-Based Compensation	17.57	20.08	25.19	20.39	9.9	13.43	8.72	11.42	11.51	8.57	Upgrade
Other Operating Activities	-9.98	15.8	7.87	13.67	3.84	3.48	-0.09	62.36	-0.2	11.03	Upgrade
Operating Cash Flow	-90.9	-108.09	-107.83	-79.29	-49.17	-53.96	-45.42	-38.37	-35.34	-5.65	Upgrade
Capital Expenditures	-0.81	-11.82	-15.12	-11.84	-19.25	-0.81	-1.02	-2.41	-2.99	-0.94	Upgrade
Acquisitions	0	0	0	0	0	0	0	3.45	0	0	Upgrade
Change in Investments	97.68	153.54	93.83	-268.32	-48.83	70.25	-121.19	37.74	-38.58	0	Upgrade
Investing Cash Flow	96.88	141.72	78.71	-280.17	-68.07	69.44	-122.2	38.78	-41.57	-0.94	Upgrade
Share Issuance / Repurchase	0.49	0.61	2.64	358.09	29.77	71.22	17.06	0.95	139.29	117.08	Upgrade
Debt Issued / Paid	0	0	-0.24	-0.06	-0.11	-0.08	0	0.1	0	2	Upgrade
Other Financing Activities	-0.42	-	-	-2.04	-1.47	-1.19	-0.31	-0.49	-0.43	46.37	Upgrade
Financing Cash Flow	0.07	0.61	2.4	355.99	28.19	69.95	16.75	0.56	138.86	165.44	Upgrade
Exchange Rate Effect	0	0	0	0	0	0	-0.77	-0.14	-0.01	-0.01	Upgrade
Net Cash Flow	6.04	34.24	-26.73	-3.47	-89.05	85.43	-151.65	0.82	61.94	158.84	Upgrade
Free Cash Flow	-91.71	-119.91	-122.95	-91.14	-68.42	-54.77	-46.44	-40.78	-38.33	-6.59	Upgrade
Free Cash Flow Margin	-2547.50%	-	-1639.39%	-	-27366.80%	-3397.83%	-2511.47%	-2802.61%	-1652.87%	-1152.27%	Upgrade
Free Cash Flow Per Share	-9.10	-12.08	-12.54	-10.70	-10.67	-8.92	-10.64	-11.25	-15.04	-5.66	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).